2 - Generic protein purification process

 

Value proposition / USP:

Proteins that are expressed recombinantly or produced synthetically are often not good enough in functionality and stability. In addition, often-used chromatography-based purification is laborious and expensive. We are able to set up an optimized, robust, patented, generic process for the production, purification, and crystallization of high-grade proteins. In the case of the 20S, 26S/30S and immunoproteasome, it generated large quantities of protein and allowed hundreds of crystals to be grown that routinely diffracted to high resolution. Further tests with HDAC and fatty acid synthase were equally successful.

 

Business model:

  • Sub-licensing of relevant IP (exclusive / non-exclusive)
  • Knowledge transfer & training

 

Suggested further reading:

 

Schrader, J.; Henneberg, F.; Mata, R.; Tittmann, K.; Schneider, T.; Stark, H.; Bourenkov, G.; Chari, A.: The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science Research Report, Vol. 353, Issue 6299, pp. 594-598 (2016)

 

Download: http://science.sciencemag.org/content/353/6299/594

 

 

Haselbach, D.; Schrader, J.; Lambrecht, F.; Henneberg, F.; Chari, A.; Stark, H.: Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs. Nat. Commun. 8, 15578 doi: 10.1038/ncomms15578 (2017)

 

Download: https://www.nature.com/articles/ncomms15578

Joint press release with NovAliX, 27th March 2018

"NovAliX enters into cooperation agreement with ProteoPlex"

Press release EMBL,

4th Aug 2016:

"Every atom counts"

EMBL Science,

8th Aug 2016:

"Blocking the cell's waste disposal unit"